Market Research Reports

Peptide Therapeutics Market (by Applications, by Route of Administration, and by Marketing Status) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020

104pages
Published Date: 2015-04-27
 

Description



The global peptide therapeutics market report provides detailed analysis, market size, and forecast for therapeutic peptides approved for various indications. The market is studied from four major perspectives: applications, route of administration, marketing status, and geography. Application segments of the global peptide therapeutics market have been further sub-segmented by major branded peptide drugs approved by regulatory authorities across the globe. Various applications considered in the report include metabolic disorders, hematological disorders, cancer, cardiovascular disorders, central nervous system disorders, infection, gastrointestinal disorders, respiratory disorders, acromegaly, and others. Market size and forecast for leading drugs such as Angiomax, Copaxone, Forteo, Sandostatin, Velcade, Victoza, and Zoladex has been included along with in-depth market analysis. Segmentation by marketing status explains the impact of generic drugs on the overall peptide therapeutics market. Further, market segmentation of peptide drugs by route of administration provides quantitative insights into the growing demand for convenient methods for peptide drug administration. Details on peptide drug approvals, patent expiry, mergers, acquisitions, strategic agreements, disease prevalence and other major events have been included in respective market segments.

The global peptide therapeutics market report provides market estimation and forecast for more than fifteen branded peptide drugs in the market. Further, the market is also segmented by major geographical regions, which include North America, Europe, Asia Pacific and Rest of the World. A list of pipeline drugs has also been provided in the report. This list includes potential peptide drugs in phases I, II, and III of clinical development. 

Emerging trends in global peptide API production, such as development of new peptide API production technologies and strategic agreements in peptide API production have been discussed. The report also profiles key peptide API suppliers. An overview of regulatory policies has also been provided in the global peptide therapeutics market report. Based on our in-depth analysis and comprehensive market study, key factors driving and restraining the market have been discussed. A detailed event impact analysis considers regulatory approvals, patent expiry of major drugs, drug recalls and other factors in the peptide therapeutics market.  The research study also incorporates the competitive scenario in these regions, where market share of seven major players in 2013 has also been provided. Relevant recommendations have been provided for new entrants as well as existing market players to help them establish a strong presence in the market and increase their share. Fifteen major players have been profiled which include Amgen, Inc., AstraZeneca plc, Bachem Holding AG, CordenPharma International GmbH, Eli Lilly & Co., Ipsen S.A., Lonza, Inc., Merck & Co., Novartis AG, Novo Nordisk A/S, PolyPeptide Group, Roche Holdings AG, Sanofi, Takeda Pharmaceutical Company Limited, and Teva Pharmaceutical Industries Limited. The 104 pages global peptide therapeutics market report includes 30 figures and charts, and 14 tables. 

Market size and forecast in terms of USD million for each segment in the global peptide therapeutics market has been provided for the period 2012 to 2020, considering 2012 and 2013 as the base years. The report also provides the compounded annual growth rate (CAGR %) for each market segment for the forecast period 2014 to 2020. The peptide therapeutics market has been estimated using a bottom-up approach, where market size estimates for each drug have been summed-up to arrive at the total market size. Market forecasts have been derived considering the effect of generic drug approvals, drug recalls, disease prevalence, patent term extension, box warning and various other factors. Inputs from industry experts and key opinion leaders have validated and further refined our market estimates.   

The global peptide therapeutics market has been segmented as below:
  • Global Peptide Therapeutics Market, by Application
    • Cancer
      • Zoladex (goserelin)
      • Velcade (bortezomib)
      • Lupron/ Enantone/ Eligard (leuprorelin)
      • Others
    • Cardiovascular
      • Angiomax (bivalirudin)
      • Integrilin (eptifibatide)
    • Central Nervous System
      • Copaxone (glatiramer)
    • Metabolic Disorders
      • Victoza (liraglutide)
      • Byetta (exenatide)
      • Others
    • Infection
      • Incivek (telaprevir)
      • Victrelis (boceprevir)
    • Hematological Disorders
      • Firazyr (icatibant)
      • Kalbitor (ecallantide)
    • Gastrointestinal Disorders
      • Gattex (teduglutide)
      • Linzess (linaclotide)
    • Respiratory Disorders
    • Acromegaly
    • Other Applications
  • Global Peptide Therapeutics Market, by Route of Administration
    • Parenteral
    • Oral
  • Global Peptide Therapeutics Market, by Marketing Status
    • Branded
    • Generic
  • Global Peptide Therapeutics Market, by Geography
    • North America
    • Europe
    • Asia Pacific
    • Rest of the World

Table of Contents



Chapter 1 Introduction
1.1 Report Description
1.2 Market Segmentation
1.3 Research Methodology
1.4 List of Abbreviations
1.5 Assumptions and Stipulations

Chapter 2 Executive Summary
2.1 Market Snapshot: Global Peptide Therapeutics Market (2013 & 2020)
2.2 Global Peptide Therapeutics Market, by Applications, 2013 (USD Million)

Chapter 3 Global Peptide Therapeutics Market Overview
3.1 Introduction
3.2 Emerging Trends in Peptide Therapeutics Market
      3.2.1 Trends in Peptide Manufacturing Technology
      3.2.2 Trends in Peptide API Supply
3.3 Market Dynamics
      3.3.1 Drivers
              3.3.1.1 Increase in cancer and diabetes patient population to propel the growth of new peptides
              3.3.1.2 Rich R&D pipeline of peptide drugs is expected to drive growth
              3.3.1.3 Technological advancements have reduced total production cost of peptides
      3.3.2 Restraints
              3.3.2.1 Increasing complexity of peptides is a huge challenge for API manufacturers
              3.3.2.2 Lack of regulatory standards
      3.3.3 Opportunities
              3.3.3.1 Generic peptides market to flourish with patent cliff expected during the forecast period
              3.3.3.2 Biotech firms collaborating with large pharmaceutical companies to explore further growth
3.4 Regulatory Scenario
3.5 Porter’s Five Forces Analysis: Global Peptide Therapeutics Market
      3.5.1 Bargaining Power of Suppliers
      3.5.2 Bargaining Power of Buyer
      3.5.3 Threat of Substitutes
      3.5.4 Threat of New Entrants
      3.5.5 Competitive Rivalry
3.6 Event Impact Analysis
      3.6.1 Event Impact Analysis: Global Peptide Therapeutics Market
3.7 Market Attractiveness Analysis
      3.7.1 Market Attractiveness Analysis of Global Peptide Therapeutics Market, by Geography, 2013
3.8 Market Share Analysis

Chapter 4 Global Peptide Therapeutics Market, by Applications
4.1 Introduction
      4.1.1 Global Peptide Therapeutics Market Revenue, by Application, 2012 – 2020 (USD Million)
4.2 Cancer
      4.2.1 Global Cancer Peptide Therapeutics Market  Revenue, 2012 – 2020 (USD Million)
      4.2.2 Zoladex (goserelin)
      4.2.3 Velcade (bortezomib)
      4.2.4 Lupron/ Enantone/ Eligard (leuprorelin)
      4.2.5 Others
4.3 Cardiovascular
      4.3.1 Global Cardiovascular Disorders Peptide Therapeutics Market  Revenue, 2012 – 2020 (USD Million)
      4.3.2 Angiomax (bivalirudin)
      4.3.3 Integrilin (eptifibatide)
4.4 Central Nervous System
      4.4.1 Global Central Nervous System Peptide Therapeutics Market  Revenue, 2012 – 2020 (USD Million)
      4.4.2 Copaxone (glatiramer)
4.5 Metabolic Disorders
      4.5.1 Global Metabolic Disorders Peptide Therapeutics Market  Revenue, 2012 – 2020 (USD Million)
      4.5.2 Victoza (liraglutide)
      4.5.3 Byetta (exenatide)
      4.5.4 Others
4.6 Infection
      4.6.1 Global Infection Peptide Therapeutics Market  Revenue, 2012 – 2020 (USD Million)
      4.6.2 Incivek (telaprevir)
      4.6.3 Victrelis (boceprevir)
4.7 Hematological Disorders
      4.7.1 Global Hematological Disorders Peptide Therapeutics Market  Revenue, 2012 – 2020 (USD Million)
      4.7.2 Firazyr (icatibant)
      4.7.3 Kalbitor (ecallantide)
4.8 Gastrointestinal Disorders
      4.8.1 Global Gastrointestinal Disorders Peptide Therapeutics Market  Revenue, 2012 – 2020 (USD Million)
      4.8.2 Gattex (teduglutide)
      4.8.3 Linzess (linaclotide)
4.9 Respiratory Disorders
      4.9.1 Global Respiratory Disorders Peptide Therapeutics Market  Revenue, 2012 - 2020 (USD Million)
4.10 Acromegaly
      4.10.1 Global Acromegaly Peptide Therapeutics Market  Revenue, 2012 – 2020 (USD Million)
4.11 Other Applications
      4.11.1 Global Other Applications Peptide Therapeutics market  Revenue, 2012 - 2020 (USD Million)

Chapter 5 Global Peptide Therapeutics Market, by Route of Administration
5.1 Introduction
      5.1.1 Global Peptide Therapeutics Market Revenue, by Route of Administration, 2012 - 2020 (USD Million)
5.2 Parenteral Route of Administration
      5.2.1 Global Peptide Therapeutics Market  Revenue, by Parenteral Route of Administration, 2012 - 2020 (USD Million)
5.3 Oral Route of Administration
      5.3.1 Global Peptide Therapeutics Market  Revenue, by Oral Route of Administration, 2012 - 2020 (USD Million)

Chapter 6 Global Peptide Therapeutics Market, by Marketing Status
6.1 Introduction
      6.1.1 Global Peptide Therapeutics Market Revenue, by Marketing Status, 2012 - 2020 (USD Million)
6.2 Branded Peptide Therapeutics
      6.2.1 Global Branded Peptide Therapeutics Market  Revenue, 2012 - 2020 (USD Million)
6.3 Generic Peptide Therapeutics
      6.3.1 Global Generic Peptide Therapeutics Market  Revenue, 2012 - 2020 (USD Million)

Chapter 7 Global Peptide Therapeutics Pipeline Overview
7.1 Introduction
      7.1.1 Global Peptide Therapeutics Pipeline Overview

Chapter 8 Global Peptide Therapeutics Market, by Geography
8.1 Introduction
      8.1.1 Global Peptide Therapeutics Market Revenue, by Geography, 2012 - 2020 (USD Million)
8.2 North America
      8.2.1 North America Peptide Therapeutics Market  Revenue, 2012 - 2020 (USD Million)
8.3 Europe
      8.3.1 Europe Peptide Therapeutics Market  Revenue, 2012 - 2020 (USD Million)
8.4 Asia Pacific
      8.4.1 Asia Pacific Peptide Therapeutics Market  Revenue, 2012 - 2020 (USD Million)
8.5 Rest of the World
      8.5.1 Rest of the World Peptide Therapeutics Market  Revenue, 2012 - 2020 (USD Million)

Chapter 9 Recommendations
9.1 Rigorous research and development (R&D) would yield new products
9.2 Facility expansion in emerging economies
9.3 Rapid inorganic growth through acquisitions

Chapter 10 Company Profiles
10.1 Amgen, Inc.
      10.1.1 Company Overview
      10.1.2 Financial Overview
      10.1.3 Product Portfolio
      10.1.4 Business Strategies
      10.1.5 Recent Developments
10.2 AstraZeneca plc
      10.2.1 Company Overview
      10.2.2 Financial Overview
      10.2.3 Product Portfolio
      10.2.4 Business Strategies
      10.2.5 Recent Developments
10.3 Bachem Holding AG
      10.3.1 Company Overview
      10.3.2 Financial Overview
      10.3.3 Product Portfolio
      10.3.4 Business Strategies
      10.3.5 Recent Developments
10.4 CordenPharma International GmbH
      10.4.1 Company Overview
      10.4.2 Financial Overview
      10.4.3 Product Portfolio
      10.4.4 Business Strategies
      10.4.5 Recent Developments
10.5 Eli Lilly and Company
      10.5.1 Company Overview
      10.5.2 Financial Overview
      10.5.3 Product Portfolio
      10.5.4 Business Strategies
      10.5.5 Recent Developments
10.6 Ipsen S.A.
      10.6.1 Company Overview
      10.6.2 Financial Overview
      10.6.3 Product Portfolio
      10.6.4 Business Strategies
      10.6.5 Recent Developments
10.7 Lonza Group Ltd.
      10.7.1 Company Overview
      10.7.2 Financial Overview
      10.7.3 Product Portfolio
      10.7.4 Business Strategies
      10.7.5 Recent Developments
10.8 Merck & Co., Inc.
      10.8.1 Company Overview
      10.8.2 Financial Overview
      10.8.3 Product Portfolio
      10.8.4 Business Strategies
      10.8.5 Recent Developments
10.9 Novartis AG
      10.9.1 Company Overview
      10.9.2 Financial Overview
      10.9.3 Product Portfolio
      10.9.4 Business Strategies
      10.9.5 Recent Developments
10.10 Novo Nordisk A/S
      10.10.1 Company Overview
      10.10.2 Financial Overview
      10.10.3 Product Portfolio
      10.10.4 Business Strategies
      10.10.5 Recent Developments
10.11 PolyPeptide Group
      10.11.1 Company Overview
      10.11.2 Financial Overview
      10.11.3 Product Portfolio
      10.11.4 Business Strategies
      10.11.5 Recent Developments
10.12 Roche Holdings AG
      10.12.1 Company Overview
      10.12.2 Financial Overview
      10.12.3 Product Portfolio
      10.12.4 Business Strategies
      10.12.5 Recent Developments
10.13 Sanofi
      10.13.1 Company Overview
      10.13.2 Financial Overview
      10.13.3 Product Portfolio
      10.13.4 Business Strategies
      10.13.5 Recent Developments
10.14 Takeda Pharmaceutical Company Limited
      10.14.1 Company Overview
      10.14.2 Financial Overview
      10.14.3 Product Portfolio
      10.14.4 Business Strategies
      10.14.5 Recent Developments
10.15 Teva Pharmaceutical Industries Ltd.
      10.15.1 Company Overview
      10.15.2 Financial Overview
      10.15.3 Product Portfolio
      10.15.4 Business Strategies
      10.15.5 Recent Developments

List of Figures

FIG. 1 Peptide Therapeutics Market Segmentation
FIG. 2 Global Peptide Therapeutics Market, by Applications, 2013 (USD Million)
FIG. 3 Porter’s Five Forces Analysis: Global Peptide Therapeutics Market
FIG. 4
FIG. 5 Market Attractiveness Analysis of Global Peptide Therapeutics Market, by Geography, 2013
FIG. 6 Market Share Analysis of Global Peptide Therapeutics Market, by Key Players, 2013 (Value %)
FIG. 7 Global Central Nervous System  Peptide Therapeutics Market Revenue, 2012 – 2020 (USD Million)
FIG. 8 Global Respiratory Disorders Peptide Therapeutics Market Revenue, 2012 - 2020 (USD Million)
FIG. 9 Global Other Applications Peptide Therapeutics Market Revenue, 2012 - 2020 (USD Million)
FIG. 10 Global Peptide Therapeutics Market  Revenue, by Parenteral Route of Administration, 2012 - 2020 (USD Million)
FIG. 11 Global Peptide Therapeutics Market  Revenue, by Oral Route of Administration, 2012 - 2020  (USD Million)
FIG. 12 Global Branded Peptide Therapeutics Market  Revenue, 2012 - 2020 (USD Million)
FIG. 13 Global Generic Peptide Therapeutics Market  Revenue, 2012 - 2020 (USD Million)
FIG. 14 North America Peptide Therapeutics Market  Revenue, 2012 - 2020  (USD Million)
FIG. 15 Europe Peptide Therapeutics Market  Revenue, 2012 - 2020  (USD Million)
FIG. 16 Asia Pacific Peptide Therapeutics Market  Revenue, 2012 - 2020  (USD Million)
FIG. 17 Rest of the World Peptide Therapeutics Market  Revenue, 2012 - 2020  (USD Million)
FIG. 18 Amgen, Inc: Annual Revenue, 2011 – 2013 (USD Million)
FIG. 19 AstraZeneca plc: Annual Revenue, 2011 – 2013 (USD Million)
FIG. 20 Bachem Holding AG: Annual Revenue, 2011 – 2013 (USD Million)
FIG. 21 Eli Lilly and Company: Annual Revenue, 2011 – 2013 (USD Million)
FIG. 22 Ipsen S.A.: Annual Revenue, 2011 – 2013 (USD Million)
FIG. 23 Lonza Group Ltd.: Annual Revenue, 2011 – 2013 (USD Million)
FIG. 24 Merck & Co., Inc.: Annual Revenue, 2011 – 2013 (USD Million)
FIG. 25 Novartis AG Annual Revenue: 2011 – 2013 (USD Million)
FIG. 26 Novo Nordisk A/S Annual Revenue: 2011 – 2013 (USD Million)
FIG. 27 Roche Holdings AG: Annual Revenue: 2011 – 2013 (USD Million)
FIG. 28 Sanofi: Annual Revenue, 2011 – 2013 (USD Million)
FIG. 29 Takeda Pharmaceutical Co. Ltd.: Annual Revenue: 2011 – 2013 (USD Million)
FIG. 30 Teva Pharmaceutical Co. Ltd.: Annual Revenue: 2011 – 2013 (USD Million)

List of Tables

TABLE 1 Market Snapshot: Global Peptide Therapeutics Market (2013 & 2020)
TABLE 2 Event Impact Analysis: Global Peptide Therapeutics Market
TABLE 3 Global Peptide Therapeutics Market Revenue, by Application, 2012 – 2020 (USD Million)
TABLE 4 Global Cancer Peptide Therapeutics Market  Revenue, 2012 – 2020 (USD Million)
TABLE 5 Global Cardiovascular Disorders Peptide Therapeutics Market  Revenue, 2012 – 2020 (USD Million)
TABLE 6 Global Metabolic Disorders Peptide Therapeutics Market  Revenue, 2012 – 2020 (USD Million)
TABLE 7 Global Infection Disorders Peptide Therapeutics Market  Revenue, 2012 – 2020 (USD Million)
TABLE 8 Global Hematological Disorders Peptide Therapeutics Market  Revenue, 2012 – 2020 (USD Million)
TABLE 9 Global Gastrointestinal Disorders Peptide Therapeutics Market  Revenue, 2012 – 2020 (USD Million)
TABLE 10 Global Acromegaly Peptide Therapeutics Market  Revenue, 2012 – 2020 (USD Million)
TABLE 11 Global Peptide Therapeutics Market Revenue, by Route of Administration, 2012 - 2020 (USD Million)
TABLE 12 Global Peptide Therapeutics Market Revenue, by Marketing Status, 2012 - 2020 (USD Million)
TABLE 13 Global Peptide Therapeutics Market Pipeline Overview
TABLE 14 Global Peptide Therapeutics Market Revenue, by Geography, 2012 - 2020 (USD Million)

Enquiry Before Buying


Free Market Analysis



Therapeutic peptides are defined as short amino acid chains that have potential in managing disease symptoms, and in some cases cure them. The industry defines peptides as molecules shorter than 100 amino acids; while longer amino acid chains can be monoclonal antibodies and proteins. Insulin was the first peptide to be isolated and administered therapeutically, and is still the most commonly prescribed peptide, having been used for over half a century. Peptides have been explored for the treatment of various conditions such as cancer, cardiovascular disorders, respiratory disorders, blood disorders, central nervous system disorders and various others.  

The peptide therapeutics market has developed at a significant pace in the recent past, leading to unparalleled growth in the number of regulatory approvals received in 2012. Thus, the increase in number of approved peptide-based drug products and expanding range of medical indications projects the increasing maturity of peptides as a class of pharmaceutical actives. Therapeutic peptides are approved for various application areas such as cancer, cardiovascular, central nervous system, gastrointestinal, infection, metabolic, pain, and respiratory. Cancer was estimated to be the largest application segment of the peptide therapeutics market in 2013; while the respiratory segment is expected to grow at the highest CAGR, due to the recent approval of Surfaxin (lucinactant). Major drugs driving growth of the overall peptide therapeutics market include Angiomax, Copaxone, Forteo, Sandostatin, Velcade, Victoza and Zoladex. As these drugs lose their patent exclusivity in the near future, the market for generic peptide drugs would flourish. However, difficulty in synthesis of complex peptides has restricted growth of the generic peptide drugs market. 

Patent expiry has been the prime factor impeding market growth; while at the same time has also allowed deeper market penetration in low and middle income countries. The market is also restrained due to unavailability of convenient routes of drug administration, and lower drug stability at room temperature. Scientists, however, are trying to overcome these drawbacks through consistent research and development. With an escalating number of peptide therapeutic drug approvals and consistent launch of generics, the demand for peptide APIs is expected to rise in the near future. Hence, API manufacturers are trying to optimize economies of scale to reduce costs and also meet the rising peptide API demand. Thus, the supply side of the peptide therapeutics value chain would decide the fate of the global market.   

The global peptide therapeutics market is largely concentrated in the western countries of North America and Europe, which account for more than 60% of the market share. Although these regions are currently the largest market segments, the compounded annual growth rate of the market in these regions is expected to be slower as compared to Asia Pacific. India, China and Japan are major countries driving the peptide therapeutics market in the Asia Pacific region. Japan is the second-largest individual pharmaceutical market, while India and China have large patient population due to high disease prevalence. Rapidly developing economy and increasing awareness about various disease treatments are other factors driving the market. India and China have emerged as major peptide API suppliers globally.    

Key players in the market include Amgen, Inc., AstraZeneca plc, Eli Lilly & Co., Ipsen S.A., Merck & Co., Novartis AG, Novo Nordisk A/S, Roche Holdings AG, Sanofi, Takeda Pharmaceutical Company Limited, and Teva Pharmaceutical Industries Limited. Leading API manufacturers include Bachem Holding AG, PolyPeptide Group.  Peptisyntha Inc and Lonza Inc.   

peptide-therapeutics-market

 

To get discount on this report, just click on the button below.

To receive brochure, please click on the button below.

Share This Market Study!  

Upcoming Report

Payment
Copyright @ Transparency Market Research